HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IGI

This article was originally published in The Rose Sheet

Executive Summary

Consumer products first half revenues dropped 16% "due largely to shifting of customer delivery schedules" that have an impact on when revenues are recorded, the company reported Sept. 4. IGI expects "to see an acceleration of orders from customers who needed to reduce their first half inventories" in the consumer division and an "evening out" of revenues by year's end. The firm's Novasome microencapsulation technology was incorporated in two Connie Stevens Forever Spring skin care products during the first half of the year. IGI also started receiving revenues from Johnson & Johnson's Roc and ph5.5 Novasome products during the same period. Overall, IGI net sales in the first half declined 12% to $15.7 mil. and 17.1% to $7.6 mil. in the second quarter. The company reported a net loss of $1.6 mil. through six months...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005798

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel